EvaluatePharma - Sanofi-Aventis - Worldwide

Sanofi-Aventis

All Financial Data in US $ (mln)Show in reporting currency

Worldwide

Overview

Company News

Phase 3 Trial of Aflibercept in Second-Line Metastatic Colorectal Cancer to Continue as Planned at Recommendation of Independent Data Monitoring Committee
Sanofi-Aventis (September 08, 2010)

Phase 3 Trial of Aflibercept in Second-Line Metastatic Colorectal Cancer to Continue as Planned at Recommendation of Independent Data Monitoring Committee
Regeneron Pharmaceuticals (September 08, 2010)

Daily Market Movers (2 Sep 2010)

(September 03, 2010)

Largest Atrial Fibrillation Registry Reveals Poor AF Control and High Rates of Cardiovascular Hospitalization
Sanofi-Aventis (September 01, 2010)

Teriflunomide Significantly Reduced Annualized Relapse Rate and was Well Tolerated in MS Patients
Sanofi-Aventis (August 30, 2010)

Genzyme Confirms Receipt of Unsolicited Proposal
Genzyme (August 30, 2010)

Sanofi-aventis Announces Non-Binding Offer to Acquire Genzyme
Sanofi-Aventis (August 29, 2010)

Sanofi-aventis Announces Non-Binding Offer to Acquire Genzyme
Genzyme (August 29, 2010)

FDA Accepts Sanofi Pasteur's Application to Expand Indication of Menactra® Vaccine to Infants and Toddlers
Sanofi-Aventis (August 26, 2010)

Momenta Pharmaceuticals Provides Litigation Update
Momenta Pharmaceuticals (August 26, 2010)

Displaying 10 out of a possible 2015 unique stories.
Results Sorted By date
Display All Stories

EvaluatePharma® - the premier source for pharma and biotech analysis.

Expert integration of financial and product data across historic and forecast timeframes (1986 to 2016) delivers a vast array of analytics by product, company, therapy area, EphMRA ATC code, technology, patent status, deals, license revenues and much more.

Company Profile



Profile	Headquartered in France, Sanofi-Aventis (NYSE: SNY) is the renamed Sanofi-Synthélabo following the AUG 2004 acquisition of Aventis. Sanofi-Synthélabo was created in MAY 1999 through the merger-of-equals between Sanofi and Synthélabo.
Listed or Private Company	Listed
Company Classification	Global Majors; Generic
Company Website	Website

Full Company Profile Information

EventAnalyzer - Last Key Event


Closing Price DateClosing Price Date	EventAnalyzer Note	Market Cap (US $m)	Change (%)	Change (+$m)
9/2/2010	2 Sep: Shares continue to fall as Genzyme rejects company's acquisition offer on 30 Aug, stating that the offer of $69 per share, or $18.5bn, undervalues the company.	74,289	-0.5%	-393

Top 3 Products (Worldwide Sales 2007/08)

				Annual Sales WW - Sales		Growth per Year (%)
Rank¹	Product	Generic Name	Therapeutic Subcategory	2007	2008	2008
1	Lovenox/Clexane	enoxaparin sodium	Anti-coagulants	3,582²	4,023³	+12%
2	Lantus	insulin glargine	Anti-diabetics	2,785⁴	3,600⁵	+29%
3	Plavix	clopidogrel bisulfate	Platelet aggregation inhibitors	3,095⁶	3,591⁷	+16%

Note: Shaded Cells⁸

RX Sales Chart

Sanofi-Aventis	Data		Growth
	2007	2008	2008
Revenues By Segment
Pharmaceuticals
Pharmaceuticals Sales (In-depth)
Rx & OTC Pharmaceuticals
Prescription (Rx) Pharmaceuticals	36,657⁹	38,458¹⁰	+5%

Therapy Area Focus in 2008

Sanofi-Aventis
	2008
WW Rx & OTC Sales By Therapy Area
Main Categories
Blood	7,615
Cardiovascular¹¹	3,159
Central Nervous System¹²	3,108
Dermatology	584
Endocrine	4,548
Gastro-Intestinal	106
Genito-Urinary	575
Musculoskeletal	1,121
Oncology & Immunomodulators¹³	5,239
Respiratory	1,681
Systemic Anti-Infectives	4,660
Other Rx & OTC Pharma	7,830

EvaluatePharma® Coverage of Marketed and Pipeline Products


	Product Count
Sanofi-Aventis ¹⁴	709

2009 Product Sales analysis
2009 Pharmaceutical Sales
2009 Market Share & Global Ranking
Download to Excel
Search 2 yrs of company press releases


EP Vantage - last 6 months

Gene therapy players sensing light at the end of the tunnel (August 25, 2010)

Sanofi most likely to face Pfizer in Genzyme battle as price wrangles continue (August 23, 2010)

Merck calls a go-slow on oral vernakalant (August 12, 2010)

Bayer’s Xarelto hot on the heels of Pradaxa (August 05, 2010)

Therapeutic focus – ALS field entering pivotal stage (August 02, 2010)

Displaying 5 out of a possible 37 unique stories.
Results Sorted By date
Display All Stories

Ranked on:
Annual Sales WW
2008

Group Total: Equals the sum of values in report based on report grouping.

Note: Where Top 5,10,100 etc filters have been applied, the aggregate value relates to the total of the original unfiltered group - not the displayed filtered data. Where n/a appears, a value has been hidden but is included in Group Total.

Examples:

e.g. Top 100 drugs reports. These are not grouped but are filtered to show only the top 100 products by sales in a particular year. The Group Total displayed is equal to the sum of all data within Evaluate Pharma - not just the top 100 products i.e. total market size.

e.g. Global Majors - Top 10 products. Report is grouped by Company and filtered to show only the top 10 products by sales in a particular year. Group Totals are displayed for each company and are equal to the sum of all available data for that company - not just the top 10 products.

XXXXXXX XXXXXXX:

XXXXXX: XXXX XX-X, XXXX XX:
XXX XXXXX XX XXXXXXX, XXX XXXXXXX XXX XXXXXXXXX XXXXXX XXXXXXX XX XXX XXXXXX, XXXXXXX €X,XXX XXXXXXX XX XXXX, X XXXX XX X.X% XX X XXXXXXXX XXXXX XXX XX XX.X% XX X XXXXXXXXXX XXXXX. XXX XXXXXXX XXXXXXXX XXXXXX XXXXXX XXXXXX XXX XXXXX XXXXXXX: XX.X% XX XXX XXXXXX XXXXXX, X.X% XX XXXXXX, XXX XX.X% XX XXX “XXXXX XXXXXXXXX” XXXXXX. XX XXX XXXXXX XXXXXX, XXXXXXXXX XXX XX XXXXXXX XXXXXXXXXXX XXXXXXX XXX XXXX XXXXXX XXXXXX.

XXXXXXX XXXXXXX:

XXXXXX:XXXX XX-X, XXXX XX:
XXXX XXXX XX X XXXXX, XXX XXXXX XX XXXXXXX®, XXX XXXXXXX XXX XXXXXXXXX XXXXXX XXXXXXX XX XXX XXXXXX, XXXX XX XX.X% XX X XXXXXXXXXX XXXXX XX €X,XXX XXXXXXX. XX XXX XXXXXX XXXXXX, XXX XXXXXXX XXXXXXXX XXXXXX XX XX.X% XX X XXXXXXXXXX XXXXX XX €X,XXX XXXXXXX. XX XXXXXX, XXXXX XXX XXXXXXXX XXXXXXXXX XXXXXXXX XX XXXXXXX XXXXXXX XXXXXXXXXXXX (XXXXXXXXX XXX XXXXXXXXXX XX XXXXXXX XXXXXXX XX XXXXX XXXXX XXXXXXXXXX XX XX XXXXXXXX XXXX XXXXXXX), XXXXXXX® XXXXXXXX XXXXXX XX X.X% XX X XXXXXXXXXX XXXXX, XX €XXX XXXXXXX (XXXXXX XXXXX XXXXXX XX XXX XXXXXX XXXXXXX XX XX.X% XX X XXXXXXXXXX XXXXX).

XXXXXX: XX XXXX XXXXXXX (XX XXX XXXX):
XXXXXX-XXXXXXX XXX XXXXX XX XXXXXXX®, XXX XXXXXXX XXX XXXXXXXXX XXXXXX XXXXXXX XX XXX XXXXXX, XXXX XX X.X% XX €XXX XXXXXXX. XX XXX XXXXXX XXXXXX, XXX XXXXXXX XXXXXXXX XXXXXX XX X.X%. XX XXXXXX, XXXXX XXX XXXXXXXX XXXXXXXXX XXXXXXXX XX XXXXXXX XXXXXXX XXXXXXXXXXXX (XXXXXXXXX XXX XXXXXXXXXX XX XXXXXXX XXXXXXX XX XXXXX XXXXX XXXXXXXXXX XX XX XXXXXXXX XXXX XXXXXXX), XXXXXXX® XXXXXXXX XXXXXX-XXXXX XXXXXX XX XXX XXXXXX XXXXXXX XX XX.X%, XX €XXX XXXXXXX. XXXX XXXX XX X XXXXX, XXX XXXXX XX XXX XXXXXXX XXXX XX XX.X% XX €X,XXX XXXXXXX.

XXXXXXX XXXXXXXXX XXXXXXXXXXX XXXXXXX:

XXXXXX: XXXX XX-X, XXXX XX-XX:
XXXXXXX®/XXXXXXX®
XXXXXXX® (XXXXXXXXXX XXXXXX) XX XXX XXXX XXXXXX XXXXXXX XXX XXXX XXX XXXXXXXXX XXXXXX XXXXXXX (XXXX) XX XXX XXXXX. XX XXX XXXX XXXX XX XXXXX XX XXXXXXXXX XXX XXXXXXX XXXXXXXX XX XXX XXXXXXXXX XXXXX XXX XXXXXX XXX XX XXXXXXXX XXX XXXX XXXXXXXX XXXXXXXXXXX XXXX XXX XXXXX XXXX. X XXXXXXXXXXXXX XXXXXXX XX XXXXXXXX XXXXXXX XXX XXXXXXXXXXXX XXX XXXXXXXX XXX XXXXXX XX XXXXXXX® XX XXX XXXXXXXXXXX XXX XXXXXXXXX XX XXXX XXXX XXXXXXXXXX (XXX) XXX XX XXXXX XXXXXXXX XXXXXXXXX (XXX). XX XXX XXXXXX XXX XXXXXXX XX XXXXXXXXX XX XXXXXXXX XXXXXX XXX XXX XXXXXXXXXXX XX XXX XXXXXXXXXXXXXX XX XXXX XXXXXX XXX XXXXXXXX XXXXXXXXXXX. XX XXX XXXXX XX XXXXXX XXXXXXXXXXXXXXX (XXX) XXXXXXXXXX, XXXXXXX® XXX XXXXXXXXX XX XXXX XXXXXXXXXX XXX XXXXXXXXXX XX XXX XX XXXXXXX XXXXXXXX. XXX XXXXXXX XXXXXXXX XX XXX XXXXXXX XXXXX XXX XXXXXXXXXXXX XXX XXXXXXX XX XXXXXXXX XXXXXXXXXXXXXXXXXX XX XXXXXXX XXX XXXXXXX XXXXXXXX XXXX XXXXXXX XXXXXXXX. XXXXXXX XXXXXXXX XXXXXXXXX XX XXX XXXXXXXX XXXXXXX XX XXXXXXXXXX XXXXXXXX XX XXXXXXXX XXXX XXXX XXXXXXXXXXXX XXXX XXXX XXXXXXX XXXXXXXXXXX, XXXX XX XXX XXXXXXX (XXXX XX XXX XXXXX) XX XXXXXX XXXXXXXX, XXX XXXXXXXXXXX XXXXXXX XXXX XXXX XXX XXXXXXX XXXXXXXXXX XXXX XXXXXXXX XXXXXXXXX. XXXXXXX®/XXXXXXX® XXX XXXXXXXX XXX XXXXXXXXX XX XXXXX XXX XXX XXXXXXXXXX XX XXX XX XXXXXXXX XXXXXXXXXX XXXXXXXXXX XXXXXXX XX XXX XXXXX XXXXX XXXX XX XXXXX XXX XXXXXXXXXXX, XXXXX XXXX XXXXXXXXXXX XXX XXX XXXXXXXX XXXXXXX XX XXXXXXX XXXX XXX XX XXXXXXXX XXXXXXXXXX XXXXXXXXX XXXXXXX XX XXXXXXXX XXXX. XX XXX XXXXXXXXXXXXXX XXXX, XXXXXXX® XXX XXXXXXXX XX XXX XXXXXX XXXXXX XX XXXX XXX XXX XXXXXXXXX XX XXXXXXXX XXXX XX-XXXXXXX XXXXXXXXX XXXXXXXXXX XXXXXXXXXX (XXXXX) XXXXX XX XXX XXXXXXX XX XXX XXXXXXX-XXXX XX XXXXX, XXX XXXXX XXXX XXX XXXX XXXXXXXX XX XXXX XXXX XX XXXXXXXXX XXXXXXXXX XXX XXXX XXXXXXXXXX. XXXXXXXXXX XXX XXXXXXX XX XXX XXXXXXX XXX XXX-XXXXX XXXXXXX XXXX XXXXXXX® XXX XX XXXXXX XXXX XXXXXX XXX XX XXX XXXXXXXXXXXXXXX XXXXXXXXXX XXXX XXXX XXX XXXXXXXXX XXXXX XXXX XXXXXXXXX XX XXX XXXXXXXX XXXXXXX XX XXXXXXXXXX XXXXXXX XX XXXXXXXXX XXXX. XXXXXXXXX XXXXXX XXXX XXXXX XXXXXXXX XXXXXX XX XXXXXXX® XX XXXXXXXXXX XX XXXXXXX XXXXXX XXXXXXXXXXXXXXX XXXXXX. XX XXXX XXXXXXXX XXX XXXXXXXX XXXXXXX XXX XXXXXXXX XX XXXXXXXXXXXXX XXXXXXXXXXXXXX XXXXXXX XX XXXXXXXX XXX XXXXXXX XXXXXXXX XXXXXXXXXX XXXXXX, XX XX XXXXXXX XX XXXXXXXXXXXXXXXXXXX XXXX XXX XXXX XX XXXXXX XXXXXXXX XX XXXX XX XXXXXX XXXX XXXXX X. XX XXXXX XX XXXXXXX XXXXXXXX XXXXXXXXXX, XXXXX (XXX XXXXXX XXXXXXXX XX XXXXX XXXXXXXX XXXXXX) XXX XXXXXXXXX XXXX XXX,XXX XXXXXXXX XXXXXXXXX XXXX XXXXX XXXXXXXX XXXXXXXX XX XX XXXXX XXX XXX XXX XX XXX XXXXXXXXXXX XX XXXX XXXX XX XXXXXXXXXXX XX X XXXXXXX XX XXXX XXXXXX XXXXXXX XXXXXXXX. XXXXXXXXXXX, XXX XXXXX XXXX XXXXX XXX XXXX XXXXXXXXXXXX XXXX XXXXXXX XXXXXXXXXXXXX XXXXXXXXXX XX XXX XXXXXXXXX XX XXXXXXXX XXXX XXX, XXXXXXXXX X XXXXXXXX XXXX XX XXXXXXXXXX XXXXXXXX XXXXX XXXXXXXX. XXXXXXX®/XXXXXXX® XX XXX XXXXXX XX XXXXXXXXXXXXXXX XX XXX XXXXXX XXXXXX, XXXXXXX, XXXXXX, XXXXX, XXXXX, XXX XXX XXXXXX XXXXXXX.

XXXXXXX XXXXXXX:

XXXXXX: XXXX XX-X, XXXX XX:
XXXXXX® XX XXX XXXXX XXXXXXX XXXXX XX XXX XXXXX XX XXXXXX €X XXXXXXX XX XXXXX (€X,XXX XXXXXXX XX XXXX). XXXXXX XXXX, XXX XXXXXXX XXXXXXX XXXXXX XXXXXX XXXXXX XXX XXXXX XXXXXXX. XXX XXX XXXXXXXX ® XXXXXXXXXX XXX XXXX XX XXXXXXXXXX XXXXXX ® XX XXX XXXXXXXXX XX XXXX XXXXXXXX XXXXXXXXX XXX XX XXX XXXXXX XXXXXX XXX XXX XXXXXX XX XXXXX XXXX XXXXXXX’X XXXXXX.

XXXXXX: XX XXXX XXXXXXX (XX XXX XXXX):
XXXXXX® XX XXX XXXXX XXXXXXX XXXXX XX XXX XXXXX XX XXXXXX €X XXXXXXX XX XXXXX (€X,XXX XXXXXXX).

XXXXXXX XXXXXXX:

XXXXXX: XXXX XX-X, XXXX XX:
XXXXXX®, XXX XXXXX’X XXXXXXX XXXXXXX XXXXX, XXX XXX XXXXXXX XXXXXXXXXXX XX XXX XXXXX’X XXX-XXXX XXXXXX XX XXXX. XXX XXXXXXX XXXXXXXX XXXXXX XXXXXX XX XXX XXXXX XXXXXXX: XX.X% XX XXX XXXXXX XXXXXX, XX.X% XX XXXXXX XXX XX.X% XX XXX “XXXXX XXXXXXXXX” XXXXXX, XX X XXXXXXXXXX XXXXX. XXX XXX-XXXXXXXXXX XXXXXX® XXXXXXXX® XXX XXX X XXXXXXXXXXX XXXXXX XX XXXXX XXXXXX XX XXX XXXXXX XXXXXX. XXX XXXX XX XX XXXXXXXXX XXXXXX® XX XXX XXXXXXX XXXXXXXXXXXX XX XXX XXXXX XX XXXXX.

XXXXXX: XX XXXX XXXXXXX (XX XXX XXXX):
XXXXXX®, XXX XXXXX’X XXXXXXX XXXXXXX XXXXX, XXX XXX XXXXXXX XXXXXXXXXXX XX XXX XXXXX’X XXX-XXXX XXXXXX XX XXXX. XXX XXXXXXX XXXXXXXX XXXXXX XXXXXX XX XXX XXXXX XXXXXXX: XX.X% XX XXX XXXXXX XXXXXX, XX.X% XX XXXXXX XXX XX.X% XX XXX “XXXXX XXXXXXXXX” XXXXXX. XXX XXX-XXXXXXXXXX XXXXXX®XXXXXXXX® XXX XXX X XXXXXXXXXXX XXXXXX XX XXXXX XXXXXX XX XXX XXXXXX XXXXXX. XXX XXXX XX XX XXXXXXXXX XXXXXX® XX XXX XXXXXXX XXXX-XXXXXXXX XX XXX XXXXX XX XXXXX.

XXXXXXXX XX €X:
X) +XXXX XXXXXXXX XXXXX.
XXXX
X) -XXX XXXXX XX XXXXXX XXXXXXXXXX XX XXX XXXXXXXX XXXXX XXXXXXX XXXXXXX XX XXX.

XXXXXXX XXXXXXX

XXXXXX: XX XXXX XXXXXXX (XX XXX XXXX):
XXXXXXXXX XXXXXXXX XX XXXXXX® / XXXXXXX®:

€ XXXXXXX                                XX XXXX     XXXXXX XX X XXXXXXXXXX XXXXX
XXXXXX                                     X,XXX                    +X.X%
XXXXXX XXXXXX                           X,XXX                 +XX.X%
XXXXX XXXXXXXXX                       XXX                      +XX.X%
XXXXX                                   XXXX                   +XX.X%

XXXX-XXXX XXXX XXXXX XX XXXXXX® XX XXX XXXXXX XXXXXX (XXXXXXXXXXXX XX XXX) XXXX XXXXXXX XXXXXX XXXX XX XXXX, XXXX XXXXX XXXX XXXXXXXX XX XXXXXXXXXXX XXXX X XXXXXXX XXXXXXX XX XXX XXXXX XXXX XX XXX XXXX. XX XXXXXX, XXX XXXXXXX’X X.X% XXXXXX XXXX XXXXXXXXX XXXXXXXXXXX XXXX XXXXXXX XXXXXXXXXXX XXXXXXXXX XX XXX XXXXXXXXXXX XXXXXXX XXXXX XXXXXX XX XXXXXXX, XXXXX XXX XXXXXX XXXXX XX XXXXXX®/XXXXXXX® XX XXXXXX XXXXXXXX XXXXXX XX% XX XXXXXXXX (XXX XXXXXXXXXXX, XXXX XXXXXXXXXX XXXXXXXX XX, XXXX). XX XXX “XXXXX XXXXXXXXX” XXXXXX, XXXXXX XXX XXXXXX® XXXXXXXXX XXXX XXX XXXXXXX XX XXXXX, XXXXX XXX XXXXX XXXXXXX €XX XXXXXXX XX XXX XXXXXX XXXXXXX XX XXXX (XX. €XX XXXXXXX XX XXX XXXXXX XXXXXXX XX XXXX) XXX €XXX XXXXXXX XXXX XXXX XX X XXXXX (XX. €XX XXXXXXX XX XXXX).

XXXXXX: XXXXXX-XXXXXXX XXXXX XXXXXXX (X XXX XXXX):
XXXXXX-XXXXXXX XXXXXX XX XXXXX XXXXXXX XXXX XXXXXXXXXXXXX XXXXXXX XX/XXXXX XX XXXXXXX XX XXXXXX X XXXXXXX XX XXXXXX® (XXXXXXXXXXX) XXXX XXX XXXXXX XXXXXX.

XXXXXXXX XXXXXX-XXXXXXX XXXX XXX XXXXXXXXX XXXX XXXXXXX XXXXXXXXXXX XXXXXXX XX XXXXX XXXXXXX, XXXXXX-XXXXXXX XXXXXX XXX XXXX XXXXXXXXXXX, XXXXXXXX XX XXXXXXX XX XXXXXX® XX XXXXXX-XXXXXXX XXX XXXXXXX® XX XXXXXXX-XXXXX XXXXXX, XXXXXXXXX XXXXX XXXXXXXX XXXX XX XXXXXXXXXX XXXX XXXXXXXXXX.

XXXXXX-XXXXXXX XX XXXXXXXXX XXXXXXXXXX XXX XXXXX XXX XXXXXXXXXX XXXXXXX XXX XXXX XXXXXXXXXX XXXXXX XXXXXXXXXXXX XXXXXXXX XXXXXX, XXXXXXXXX XXXXXX XXXXXXXXXX, XX XXXXXXX.

XXXXXXX XXXXXXXXX XXXXXXXXXXX XXXXXXX:

XXXXXX: XXXX XXXXXX XXXXXX, XXXX XX:
XX XXX XXXXXX XXXXXX XXX XXXXXXX XXXXX XX XXXXXXX XXXXX XXXX XXX XXXXXXXX XX XXX XXXXXXXX XXXXXX XXXXXXXX XX XXXXXXXX XXXX.

XXXXXX: XXXX XX-X, XXXX XX:
XXX XXXXXXX XXXXXXXX XXXXXX XXXX XXX XXXXXXXX XX XXXXXXX XXX XXXX-XXXX XXXXX XX XXXXXX® XX XXXXXXXXX XXXXXXXXXXXXX XXXXXXXX XXXX XXXXXXX: • XXX XXXXXX XXXXX, XXXXX XX XXXXXXXX XX XXXXXX XXX XXXXX XX XXXXXX® XX XXX XX XXX XXXXXXXX XXXX XXX XXXXX XX XXXXXXXX XXXX XXXXXX XXXXXXXXXXXX (XXX XXXXXX XXXX XX XXXX XXXXXXXXXXXXX) XXX XXX XXXXXXXXX XX XXXXXX-XXXXXXX XXX XXXXXXXXXXXXXXXX XXXXXX. XXXX XXXXX XXX XXXXXXXXX XXXXXXXXXXX (XX,XXX XXXXXXXX XXXXXXXX, XXXXXXXXX XX XXX XXXXXX-XX XXXXX). XXXXX XXX XXX XX XXX XXXXX — XXXXXX-X — XXX XXXXXXXXXX XXXXX, XXX XXXXX XXX XXXX, XXXXXX-X XXX XXXXXX-X, XXX XXXXXXX. XXX XXXXXXX XX XXXX XXXXXX-X XXX XXXXXX-X XXX XXXXXXXX XX XXXX; • XXX XXXXXXX XXXXX, XXXXX XXXX XX XXXXXXXX XXX XXXXXX XXXXXXX XX XXXXXXXXXXX XXXXXXXXX XX XX,XXX XXXXXXXX XXXX XXX XXXXXXXXX XXX XXXXXXXXXXXX XXXXXXXX XXXXXXXXXXXX. X XXXXXXX XXXX XX XXX XX XXXXXXXX XX XXX XX XXXXX XXX X XXXX XXXX XXXXXXXX XX XX XX XXXXX XX XX XXX XXX XX XXX XXXXX (XX XXXX) XX XXXXXXXX XX XXX XXXXXXXXX XXXXXXXX XXXXXXX (XXX XX XXXXXXX XXXX XXXXXXXX XX XX XX XXXXX). XXX XXXXXXXXXXX XXXXXXX XX XXXX XXX XXXXXXX XXX XXXXXXXX XX XXXX; XXX • XXXXXXXXX XX XXX XXXXXXX XXXXXXX XXX XXXXXXXXX XXXX, XXX XXXXXXXXXXX XX X XXXXXXXXX XXXXXXXXXX XXX XXXXXX® XX XXX XXXXXX XXXXXX XX XXXXXXX. XXX XXXX XXXXXXX XXXXX XX (XXXXXX XXXXX) XXX XXXXXX XXXXXXXXX XXX XXXXX XXXX XX XX XXXXXXX XX XXXXX XXX (XXXXXXXX). XXXXXXXX XX XXXXXXX XXX XXXXXXX XXX XXXXXXXX XX XXXX. X XXXXXXXXX XXXXXXXXXXXXXXX XXXX XXX XXXXXXXX XX XXXX XX XXX XXXXXXXX XXXXXXXXX XXXXXX.

Company Specific NameCardiovascular/Thrombosis

Shaded Cells

A shaded cell signifies potentially incomplete data. E.g. A shaded cell in "Change (+/-)" means there is no corresponding value, i.e. there is data for 2001, but no data for 2000. This could signify a product launch, first time disclosure of sales, a product acquisition or missing data.

A shaded cell containing n/a signifies valid data followed by blank or zero values. E.g. A shaded cell containing n/a in "Change (+/-)" means a value is present for 2000, but blank for 2001. This could signify a product disposal / withdrawal, discontinuation of disclosure or missing data.

Company Specific NameCentral Nervous System

XXXXXXXX XX €X:
X) +XX,XXX XXXXXXXXXXXXXXX.
X) +X,XXX XXXXXXXX.
X) +XXX XXXXXX XXXXXXX XXX (XX% XXXXX XX XXX XXXXX).
XXXXX XXX XXXXXXXXXX XXXXXXX XXXXX

XXXXXXXX XX €X:
X) +XXXXX XXXXXXXXXXXXXXX.
X) +XXXX XXXXXXXX.
X) +XXX XXXXXX XXXXXXX XXX (XX% XXXXX XX XXX XXXXX).
XXXXX XXX XXXXXXXXXX XXXXXXX XXXXX

Company Specific NameOncology